StreetInsider.com News Articles

Barclays Downgrades Certara Inc. (CERT) to Equalweight

Fri, 06 Mar 2026 06:19:54 -0500

(Updated - March 6, 2026 6:19 AM EST)

Barclays analyst Luke Sergott downgraded Certara Inc. (NASDAQ: CERT) from Overweight to Equalweight with a price target of $8.00.

The analyst comments "We move to the sidelines on CERT and downgrade shares to Equal Weight. The crux of our call is that we did not appreciate how much of a fixer-upper the business was. We thought that there needed to be investment in a backbone across the clinical trial continuum where CERT’s offerings could plug into and talk to each other, but it seems that there is a greater investment need across more of

Barclays Downgrades Certara Inc. (CERT) to Equalweight

Fri, 06 Mar 2026 06:19:54 -0500

(Updated - March 6, 2026 6:19 AM EST)

Barclays analyst Luke Sergott downgraded Certara Inc. (NASDAQ: CERT) from Overweight to Equalweight with a price target of $8.00.

Certara Simcyp® Simulator Results Replace Ten Human Trials for Chronic Myeloid Leukemia (CML) Therapy asciminib

Tue, 03 Mar 2026 08:00:00 -0500

Biosimulation results highlight how model-informed approaches for drug development and regulatory decision-making save time and money.

RADNOR, Pa., March 03, 2026 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced its Simcyp^® Simulator enabled physiologically-based pharmacokinetic (PBPK) modeling predictions accepted by the U.S. FDA in lieu of clinical studies to support the new drug application (NDA) for asciminib (Scemblix^®). PBPK modeling uses virtual biological systems to predict how drugs are absorbed, distributed, metabolized, and eliminated by the body, and is increasingly being applied in place of certain clinical studies

Certara Simcyp® Simulator Results Replace Ten Human Trials for Chronic Myeloid Leukemia (CML) Therapy asciminib

Tue, 03 Mar 2026 08:00:00 -0500

Biosimulation results highlight how model-informed approaches for drug development and regulatory decision-making save time and money.

Certara (CERT) Reiterated at Market Perform by Citizens: Fairly Valued

Tue, 03 Mar 2026 05:12:10 -0500

Citizens analyst Constantine Davides reiterated a Market Perform rating and {REMOVEPT} price target on Certara Inc. (NASDAQ: CERT).

The analyst commented, "We lower our 2026 revenue estimate to $427M (+2% Y/Y) from our prior $445M estimate. Our 2026 EBITDA estimate moves to $132.0M (-2% Y/Y) from our prior $145.7M estimate. We like CERT's comprehensive technology and service portfolio and believe the company stands to benefit from Mr. Resnick's leadership and background. However, we view CERT as fairly valued – at 9.4x 2026E EBITDA and at approximate parity to peer Simulations Plus (SLP, MP) – in the context of our projection for

Form 4 Certara, Inc. For: Feb 27 Filed by: Bedi Arjun

Mon, 02 Mar 2026 16:39:00 -0500

si-local-file:///var/storage/secattach/20260302/26093051.html

Form 4 Certara, Inc. For: Feb 27 Filed by: Bedi Arjun

Mon, 02 Mar 2026 16:39:00 -0500

si-local-file:///var/storage/secattach/20260302/26093051.html

Form 3 Certara, Inc. For: Feb 24 Filed by: Bedi Arjun

Mon, 02 Mar 2026 16:34:00 -0500

si-local-file:///var/storage/secattach/20260302/26092910.html

Form 3 Certara, Inc. For: Feb 24 Filed by: Bedi Arjun

Mon, 02 Mar 2026 16:34:00 -0500

si-local-file:///var/storage/secattach/20260302/26092910.html

Craig-Hallum Downgrades Certara Inc. (CERT) to Hold

Fri, 27 Feb 2026 09:23:08 -0500

Craig-Hallum analyst Matthew Hewitt downgraded Certara Inc. (NASDAQ: CERT) from Buy to Hold with a price target of $10.00.

The analyst comments "CERT’s Q4 call featured a lot of warm language about the market, the company and it’s prospects to return to faster growth. New CEO Jon Resnick, who has been in the job for 57 days, spoke about “sharpening focus,” “customer centricity,” and “execution discipline” (all reasonable concepts that we welcome), but we are left wondering if there may be heavier lifting required than we initially thought. The commitment to investors was roughly $10M in what management called “cost avoidance”

Craig-Hallum Downgrades Certara Inc. (CERT) to Hold

Fri, 27 Feb 2026 09:23:08 -0500

Craig-Hallum analyst Matthew Hewitt downgraded Certara Inc. (NASDAQ: CERT) from Buy to Hold with a price target of $10.00.

Certara Inc. (CERT) PT Lowered to $7 at BMO Capital

Fri, 27 Feb 2026 09:20:04 -0500

BMO Capital analyst Sean Dodge lowered the price target on Certara Inc. (NASDAQ: CERT) to $7.00 (from $9.00) while maintaining a Market Perform rating.

Certara to Participate in Upcoming Investor Conferences

Fri, 27 Feb 2026 08:30:00 -0500

RADNOR, Pa., Feb. 27, 2026 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced that Company management will participate in the following investor conferences:

TD Cowen 46^th Annual Health Care Conference
Date and Time: Tuesday, March 3^rd, 2026, at 3:10PM ET

Leerink Global Healthcare Conference
Date and Time: Monday, March 9^th, 2026, at 8:00AM ET

Barclays 28^th Annual Global Healthcare Conference
Date and Time: Tuesday, March 10^th, 2026, at 1:00PM ET

Live webcasts for each of the conferences will be available

Certara to Participate in Upcoming Investor Conferences

Fri, 27 Feb 2026 08:30:00 -0500

TD Cowen 46^th Annual Health Care Conference
Date and Time: Tuesday, March 3^rd, 2026, at 3:10PM ET

Leerink Global Healthcare Conference
Date and Time: Monday, March 9^th, 2026, at 8:00AM ET

Barclays 28^th Annual Global Healthcare Conference
Date and Time: Tuesday, March 10^th, 2026, at 1:00PM ET

Live webcasts for each of the conferences will be available

Certara Inc. (CERT) PT Lowered to $8 at Baird

Fri, 27 Feb 2026 06:54:23 -0500

Baird analyst Joe Vruwink lowered the price target on Certara Inc. (NASDAQ: CERT) to $8.00 (from $11.00) while maintaining a Neutral rating.

Certara Inc. (CERT) PT Lowered to $8 at Barclays

Fri, 27 Feb 2026 05:29:49 -0500

Barclays analyst Luke Sergott lowered the price target on Certara Inc. (NASDAQ: CERT) to $8.00 (from $13.00) while maintaining a Overweight rating.

Certara Inc. (CERT) PT Lowered to $10 at TD Cowen

Thu, 26 Feb 2026 14:00:21 -0500

TD Cowen analyst Brendan Smith lowered the price target on Certara Inc. (NASDAQ: CERT) to $10.00 (from $16.00) while maintaining a Buy rating.

The analyst comments "FY25 revs of $419M (+9% y/y) included +18% y/y Software growth + 3% y/y Services growth as macro uncertainties continued to impact pharma spending in Q4. New guide of 0-4% y/y topline growth leaves room to outperform given consistent biosim software trends, though new CEO is reassessing spending priorities across the business with update on reg services segment as next key catalyst to watch for."

Certara Inc. (CERT) PT Lowered to $10 at TD Cowen

Thu, 26 Feb 2026 14:00:21 -0500

TD Cowen analyst Brendan Smith lowered the price target on Certara Inc. (NASDAQ: CERT) to $10.00 (from $16.00) while maintaining a Buy rating.

Certara Inc. (CERT) PT Lowered to $10 at Leerink Partners

Thu, 26 Feb 2026 13:08:22 -0500

Leerink Partners analyst Michael Cherny lowered the price target on Certara Inc. (NASDAQ: CERT) to $10.00 (from $13.00) while maintaining a Outperform rating.

The analyst comments "We understand why the stock has been weak/ volatile—4Q software bookings declined and guidance on revenue/EBITDA came in below expectations. There certainly was an element of both market and execution dynamics that the company honed in on, yet this is also what you tend to get when you have a new CEO come in. CERT's push was to drive improved commercialization efforts, something that its broad biosimulation offerings (which have plenty of AI enablement) should

Certara Inc. (CERT) PT Lowered to $10 at Leerink Partners

Thu, 26 Feb 2026 13:08:22 -0500

Leerink Partners analyst Michael Cherny lowered the price target on Certara Inc. (NASDAQ: CERT) to $10.00 (from $13.00) while maintaining a Outperform rating.

Form 10-K Certara, Inc. For: Dec 31

Thu, 26 Feb 2026 06:55:00 -0500

si-local-file:///var/storage/secattach/20260226/26064011.html

Form 10-K Certara, Inc. For: Dec 31

Thu, 26 Feb 2026 06:55:00 -0500

si-local-file:///var/storage/secattach/20260226/26064011.html

Form 8-K Certara, Inc. For: Feb 26

Thu, 26 Feb 2026 06:24:00 -0500

si-local-file:///var/storage/secattach/20260226/26063758.html

Form 8-K Certara, Inc. For: Feb 26

Thu, 26 Feb 2026 06:24:00 -0500

si-local-file:///var/storage/secattach/20260226/26063758.html

Certara, Inc. (CERT) Misses Q4 EPS by 2c

Thu, 26 Feb 2026 06:16:47 -0500

Certara, Inc. (NASDAQ: CERT) reported Q4 EPS of $0.09, $0.02 worse than the analyst estimate of $0.11. Revenue for the quarter came in at $103.6 million versus the consensus estimate of $103.23 million.

For earnings history and earnings-related data on Certara, Inc. (CERT) click here.